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OBJECTIVE — To explore the hypothesis that CD36, a scavenger receptor and fatty acid
translocase, is upregulated in peripheral blood mononuclear cells (PBMCs) among patients with
type 2 diabetes and is a biomarker of PBMC activation and inﬂammation.
RESEARCH DESIGN AND METHODS — We used a cross-sectional observational
designtostudyamulti-racial/ethnicpopulationsampleconsistingofCaucasians,Hispanics,and
Native Americans with type 2 diabetes (n  33) and nondiabetic control subjects (n  27).
PBMC CD36 mRNA/protein and plasma high sensitivity (hs) C-reactive protein (hsCRP), hs–
interleukin-6 (hsIL-6), and adiponectin were measured.
RESULTS — Unadjusted PBMC CD36 mRNA and protein were 1.56- and 1.63-fold higher,
respectively, among type 2 diabetic subjects versus control subjects. PBMC CD36 protein was
directly associated with CD36 mRNA, plasma hsCRP, and hsIL-6 and inversely associated with
plasma adiponectin in both groups.
CONCLUSIONS — Increased CD36 expression is a biomarker of PBMC activation and
inﬂammation and may become a useful tool in cardiovascular disease risk stratiﬁcation.
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T
he prevalence of type 2 diabetes is
increasing in epidemic proportions
among minority populations. Car-
diovascular disease (CVD) is a major
cause of morbidity and mortality among
diabetic patients. New methods for risk
stratiﬁcation are needed to reduce the
burden of CVD among patients with
diabetes.
CD36, a 88-kDa transmembrane gly-
coprotein and a cell surface scavenger
receptor for oxidized low-density
lipoproteins (oxLDL), plays a critical role
in the pathogenesis of atherosclerosis and
CVD(1,2).LigationofoxLDLbyCD36in
macrophages induces activation of nu-
clear factor –light-chain enhancer of ac-
tivated B-cells (NFB) and production of
proinﬂammatory cytokines, e.g., tumor
necrosis factor / (TNF-/), interleu-
kin(IL)-1,IL-6,andinterferon/.Pro-
duction of proinﬂammatory cytokines is
reduced in CD36-deﬁcient macrophages
(2). The size of atherosclerotic lesions is
reduced by inactivation of CD36 and in-
creased by reintroduction of CD36 in
apolipoprotein E/CD36-deﬁcient mice.
CD36 expression is increased in the pres-
ence of high glucose concentrations.
Therefore,assessmentofCD36levelsmay
become a valuable tool in CVD risk strat-
iﬁcation among patients with type 2
diabetes.
The majority of previous clinical
studies of CD36 expression have been
conducted in a single racial/ethnic group.
In contrast, the present study explored
the hypothesis that there is coordinated
upregulation of peripheral blood mono-
nuclear cell (PBMC) CD36 mRNA and
protein, signaling PBMC activation and
increased production of proinﬂammatory
cytokines among non-Hispanic whites,
Hispanics, and American Indians with
type 2 diabetes.
RESEARCH DESIGN AND
METHODS
Clinical protocol
All participants were studied in the Gen-
eral Clinical Research Center at the Uni-
versity of New Mexico. We recruited
participants with (n  33) and without
(n  27) type 2 diabetes. Patients with
type 2 diabetes had two or more fasting
plasma glucose values 126 mg/dl or re-
ceived hypoglycemic medications. Non-
diabetic participants had a fasting plasma
glucose level 100 mg/dl and A1C
6.1% and were not receiving hypogly-
cemic medications. Patients with end-
stage renal disease, with liver disease, or
who were pregnant, malnourished, or re-
ceiving insulin were excluded. We ob-
tained a venous blood sample after an
overnightfastforachemistryproﬁle,lipid
panel, cytokines, high sensitivity (hs) C-
reactiveprotein(CRP),adiponectin,A1C,
nonesteriﬁed fatty acids, and PBMC
isolation.
Isolation of PBMCs, extraction of
RNA and protein, and quantiﬁcation
of CD36  mRNA and protein
PBMCs were isolated and stored at
80°C. PBMC RNA and protein were
isolated using TRIZOL reagent (Invitro-
gen, Carlsbad, CA). mRNA was reverse-
transcribed to cDNA using random
hexamer primers. Quantitative PCR was
performed using SYBR Green RT-PCR re-
agents (Applied Biosystems, Foster City,
CA) in the MiniOpticon System (Bio-Rad,
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sured using Western blot (rabbit anti-
CD36 antibody, sc9154; Santa Cruz
Technology, Santa Cruz, CA; mouse anti-
actin antibody, A4700, Sigma, St. Louis,
MO; goat anti-rabbit IgG-HRP, #172-
1019, and goat anti-mouse IgG-HRP,
#170-6516, Bio-Rad).
Statistical analysis
Pearson correlations of CD36 mRNA and
protein levels with anthropometric and
laboratory measurements were deter-
mined in diabetic and nondiabetic partic-
ipants. Means of CD36 mRNA and
protein across groups stratiﬁed by race/
ethnicity, sex, diabetes, and hypertension
statuswerecomparedusingANOVA.The
relationship of diabetes status to CD36
expressionwasassessedinmultiplelinear
regressionanalysesthatincludedmarkers
of inﬂammation, obesity, and insulin re-
sistance as covariates. Statistical analyses
were performed in SAS version 9.2.
RESULTS
Study participants
There were no signiﬁcant differences in
the distributions of age, sex, and race/
ethnicity, respectively, between diabetic
and nondiabetic participants. Male and
female non-Hispanic whites, Hispanics,
and American Indians were represented
in each group. BMI, blood pressure, tri-
glycerides, HDL cholesterol, nonesteriﬁed
fatty acids, fasting plasma glucose, A1C,
and insulin levels were higher among di-
abetic versus nondiabetic participants.
No interactions were identiﬁed between
race/ethnicity, diabetes status, and CD36
mRNA (P  0.22) or protein levels (P 
0.18).
PBMC CD36 expression and
circulating levels of biomarkers and
mediators of inﬂammation
UnadjustedCD36mRNAandproteinlev-
els were higher among diabetic versus
nondiabeticparticipants(Table1).PBMC
CD36 protein, but not CD36 mRNA, lev-
els remained higher among patients with
type 2 diabetes versus control subjects,
after adjusting for markers of inﬂamma-
tion, blood pressure, and insulin sensitiv-
ity. Plasma hsCRP, hsIL-6, and TNF-
were higher among diabetic versus non-
diabetic participants.
CD36 mRNA and protein levels were
tightly correlated among diabetic and
nondiabetic participants, respectively.
PBMC CD36 and peroxisome prolifera-
tor–activated receptor (PPAR)- mRNA
levels were directly correlated in both
groups.PBMCCD36proteinandPPAR-
mRNA levels were directly correlated
among nondiabetic participants. PBMC
CD36 mRNA and protein levels were di-
rectly correlated with plasma hsCRP and
hsIL-6 and inversely correlated with
plasma adiponectin in each group (Table
1). CD36 mRNA was inversely associated
with blood pressure among diabetic par-
ticipants(P0.02).Noassociationswere
observed between CD36 expression and
plasma HDL, LDL, or total cholesterol or
nonesteriﬁed fatty acids.
CONCLUSIONS — Our results are
in concert with previous reports demon-
strating that unadjusted PBMC CD36
mRNA and protein levels were upregu-
lated among patients with type 2 diabetes
(3,4). After adjustment for potential
confounders, only CD36 protein levels
remained higher among diabetic partici-
pants, suggesting that hyperglycemia has
a greater impact on translation versus
transcription. PBMC CD36 expression
among diabetic participants was strongly
correlated with hsCRP and hsIL-6, which
arestrongindependentpredictorsofCVD
(5–7). Therefore, increased PBMC CD36
expression is a sign of monocyte activa-
tion and a biomarker for a proinﬂamma-
tory state. PBMC CD36 mRNA and
protein levels were inversely correlated
with plasma adiponectin levels, which, in
turn, were inversely correlated with insu-
lin resistance, suggesting a pathogenic
link between insulin resistance and ath-
erosclerosis. Therefore, CD36 may be im-
portant in the pathogenesis of CVD
amongpatientswithtype2diabetes(4,8–
11). The higher age of the diabetic pa-
tients may have contributed to observed
higher levels of plasma hsCRP, hsIL-6,
and TNF- (12). Furthermore, it is rea-
sonabletospeculatethatCD36mayalso
beprotectiveinaging,sinceitmaydelay
Table 1—Unadjusted and adjusted mean CD36 mRNA/protein and Pearson product moment correlations (r)
CD36 mRNA
(log r.u.)
CD36 protein
(log r.u.)
Type 2 diabetes
Nondiabetic
control subjects Type 2 diabetes
Nondiabetic
control subjects
n 33 27 33 27
Unadjusted mean 0.23 	 0.02† 0.16 	 0.02 0.28 	 0.02§ 0.18 	 0.02
Model 1 0.21 	 0.02 0.17 	 0.02 0.27 	 0.01* 0.21 	 0.02
Model 2 0.20 	 0.02 0.18 	 0.02 0.26 	 0.01† 0.20 	 0.01
CD36 mRNA (log r.u.) NA NA r  0.64‡ r  0.63‡
PPAR- mRNA (log r.u.) r  0.73‡ r  0.72‡ r  0.33# r  0.46*
hsCRP (log mg/dl) r  0.55† r  0.21 r  0.45† r  0.43*
hsIL-6 (log pg/ml) r  0.40* r  0.49† r  0.64‡ r  0.49†
TNF- (log pg/ml) r  0.20 r  0.09 r  0.28 r  0.02
Adiponectin (log 
g/ml) r  0.61‡ r  0.67‡ r  0.60‡ r  0.56†
BMI (kg/m
2) r  0.20 r  0.03 r  0.09 r  0.17
HOMA-IR (log r.u.) r  0.18 r  0.03 r  0.12 r  0.07
QUICKI (log r.u.) r  0.20 r  0.05 r  0.16 r  0.19
Dataareleastsquaresmeans	SEMunlessotherwiseindicated.ThePvalueisfromattestofequalityofthemeans.Model1adjustsforhypertension(HTN),hsIL-6,
PPAR, adiponectin, and QUICKI. Model 2 adjusts for hsIL-6, adiponectin, and QUICKI. *P  0.05, †P  0.01, ‡P  0.001, §P  0.0001, #P  0.08. HOMA-IR,
homeostasis model assessment–insulin resistance; QUICKI, quantitative insulin sensitivity check index; r.u., relative units.
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(13).
A strength of the present study is the
inclusion of non-Hispanic whites, His-
panics, and American Indians. Limita-
tions include the cross-sectional design
and the limited number of African
Americans.
In summary, in a multiracial/ethnic
group of patients with type 2 diabetes, 1)
unadjusted PBMC CD36 mRNA and pro-
tein levels were upregulated and 2) CD36
expression was a biomarker of monocyte
activation and a proinﬂammatory state.
Additional studies are needed to assess
the use of CD36 expression in CVD risk
stratiﬁcation.
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